In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China.
Ran JingIan MorrisseyMeng XiaoTian-Shu SunGe ZhangWei KangDa-Wen GuoJalal A AramJeffrey WangEric A UttYao WangYing-Chun XuPublished in: Infection and drug resistance (2022)
order. MIC indicated an advantage over currently available azole antifungals, positioning ISA as a potential alternative to VOR for clinical management of IMIs. As with other antimicrobials, clinicians should employ stewardship and best practices in relation to potential resistance to new azole antifungals.